Latest Regulatory Engagement News

Macquarie Group reports solid 3Q26 results with robust profit growth across divisions and a strong capital surplus, underpinned by strategic technology investments and regulatory compliance.

Manuka Resources has secured a US$22.5 million loan facility and completed a A$15 million capital raise, positioning itself for a production restart in late Q2 2026 amid soaring silver and gold prices.

Actinogen Medical has completed enrolment for its pivotal XanaMIA Alzheimer's trial ahead of schedule, with a positive interim analysis supporting continuation. The company is gearing up for an open-label extension and advancing commercial and partnership strategies.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Ardea Resources has made disciplined progress on its Kalgoorlie Nickel Project’s Definitive Feasibility Study, supported by renewed Major Project Status and full funding from a Japanese consortium. Completion is on track for mid-2026 amid robust resource updates and strategic partnerships.

Patrys Limited has expanded its therapeutic portfolio by acquiring Reliis Pty Ltd, adding a proprietary injectable asset targeting delirium with near-term clinical milestones. This strategic move complements its existing biologics platform and strengthens its financial position.

Nexsen Limited has reported significant progress in its rapid diagnostic technologies, including a key FDA pre-submission for its GBS rapid sensor and a solid cash reserve post-IPO to support commercialisation efforts.

Evolution Energy Minerals has ramped up exploration at its Chikundo Copper Project while stabilising its finances and navigating regulatory hurdles in Tanzania. The company is preparing for drilling in 2026 despite a tight cash position.

NT Minerals faces ASX trading suspension but pushes forward with exploration plans at Twin Peaks and Finniss River projects, while considering capital restructuring.

Mesoblast Limited reported a 60% jump in Ryoncil sales to US$35 million for the December quarter, alongside securing a US$125 million credit facility that enhances its financial flexibility and supports ongoing clinical development.

Cynata Therapeutics has completed enrolment in major clinical trials for osteoarthritis and acute graft versus host disease, with pivotal results expected in the second quarter of 2026. The company also strengthened its patent portfolio and secured additional funding to extend its operational runway.

CurveBeam AI reported steady progress in Q2 FY26 with five new device purchase orders, a $4 million milestone payment pending receipt, and key regulatory submissions underway in the US and China.